Cipla is currently trading at Rs. 641.50, up by 7.05 points or 1.11% from its previous closing of Rs. 634.45 on the BSE.
The scrip opened at Rs. 645.20 and has touched a high and low of Rs. 645.20 and Rs. 636.80 respectively. So far 71780 shares were traded on the counter.
The BSE group ‘A’ stock of face value Rs. 2 has touched a 52 week high of Rs. 696.00 on 22-Jun-2020 and a 52 week low of Rs. 356.75 on 13-Mar-2020.
Last one week high and low of the scrip stood at Rs. 652.65 and Rs. 629.80 respectively. The current market cap of the company is Rs. 51153.86 crore.
The promoters holding in the company stood at 36.68%, while Institutions and Non-Institutions held 40.61% and 22.71% respectively.
Cipla has launched its generic version of antiviral drug remdesivir at Rs 4,000 per vial, which is among the lowest globally, and is looking to supply over 80,000 vials within the first month. Cipremi is priced at Rs 4,000 per 100 mg vial. To further ensure equitable distribution, the drug will be available through government and hospital channels only.
The company will also be donating some amount of the drug as part of its efforts to support the community in this time of need. Cipremi has been approved by the Drug Controller General of India (DCGI) for restricted emergency use in the country as part of the accelerated approval process considering the urgent and unmet medical need.
Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients.
